Suppr超能文献

慢性阻塞性肺疾病患者的皮质类固醇剂量和血糖水平与再入院率增加无关。

Corticosteroid Dosing and Glucose Levels in COPD Patients Are Not Associated with Increased Readmissions.

作者信息

McGraw Meghan, White Heath D, Zolfaghari Kiumars, Hochhalter Angela, Arroliga Alejandro, Boethel Carl

机构信息

Division of Pulmonary, Critical Care and Sleep Medicine, Baylor Scott and White Health, Temple, Texas, United States.

出版信息

Chronic Obstr Pulm Dis. 2021 Jan;8(1):117-23. doi: 10.15326/jcopdf.2020.0172.

Abstract

INTRODUCTION

Hospital admissions and readmissions for chronic obstructive pulmonary disease (COPD) exacerbations are associated with increased mortality and higher cost. The management of exacerbations with a shortened course of systemic corticosteroids has similar efficacy as compared to longer steroid courses, but actual overall steroid dose given is still variable. The outcomes associated with steroid side effects, such as hyperglycemia, need further evaluation. We hypothesized that the use of higher doses of corticosteroids, and the subsequent hyperglycemia, contributes to readmission.

METHODS

This is a retrospective study at a tertiary care referral center in central Texas between February 2014 and July 2016. Daily corticosteroid dose, blood glucose levels, and readmission rates at 30 and 31-90 days were recorded. Sample characteristics are described using descriptive statistics. A chi-square test or student's test were used to test for associations in bivariate comparisons. Multivariable logistic regression assessed the association between readmission rate and demographic and clinical characteristics.

RESULTS

There were 1120 patients admitted for COPD exacerbation between February 2014 and July 2016. A total of 57% were female, mean age was 69 years (standard deviation [SD] 12), and average body mass index (BMI) was 29.4 (SD 9.8). Of the total, 349 (31%) had diabetes prior to admission. The 30-day readmission rate was 16%, and the readmission rate from 31-90 days was 14%. The average prednisone equivalent dose per day during hospitalization was 86 mg (SD 52). A multivariable logistic regression model did not show any significant association between readmission and average daily glucose, high maximum glucose (>180 mg/dL on any reading), or prednisone equivalent administered per day.

CONCLUSION

Corticosteroid dose and hyperglycemia were not associated with an increased 30-day or 31-90-day readmission rate after COPD exacerbation discharge. In addition, using higher doses of corticosteroids instead of standard-of-care (prednisone 40 mg per day for a 5-day period) did not appear to affect the readmission rate in this cohort.

摘要

引言

慢性阻塞性肺疾病(COPD)急性加重导致的住院和再入院与死亡率增加及成本上升相关。与较长疗程的全身用糖皮质激素相比,缩短疗程治疗急性加重具有相似的疗效,但实际给予的糖皮质激素总剂量仍存在差异。与糖皮质激素副作用(如高血糖)相关的结局需要进一步评估。我们假设使用较高剂量的糖皮质激素及随后出现的高血糖会导致再入院。

方法

这是一项在德克萨斯州中部一家三级医疗转诊中心进行的回顾性研究,时间跨度为2014年2月至2016年7月。记录每日糖皮质激素剂量、血糖水平以及30天和31 - 90天的再入院率。使用描述性统计描述样本特征。采用卡方检验或学生检验进行双变量比较中的关联性检验。多变量逻辑回归评估再入院率与人口统计学和临床特征之间的关联。

结果

2014年2月至2016年7月期间,共有1120例因COPD急性加重入院的患者。其中57%为女性,平均年龄69岁(标准差[SD]12),平均体重指数(BMI)为29.4(SD 9.8)。总计349例(31%)患者入院前患有糖尿病。30天再入院率为16%,31 - 90天再入院率为14%。住院期间每日泼尼松等效剂量平均为86毫克(SD 52)。多变量逻辑回归模型未显示再入院与平均每日血糖、最高血糖值高(任何一次读数>180毫克/分升)或每日给予的泼尼松等效剂量之间存在任何显著关联。

结论

COPD急性加重出院后,糖皮质激素剂量和高血糖与30天或31 - 90天再入院率增加无关。此外,在该队列中,使用较高剂量的糖皮质激素而非标准治疗方案(泼尼松每日40毫克,共5天)似乎并未影响再入院率。

相似文献

1
Corticosteroid Dosing and Glucose Levels in COPD Patients Are Not Associated with Increased Readmissions.
Chronic Obstr Pulm Dis. 2021 Jan;8(1):117-23. doi: 10.15326/jcopdf.2020.0172.
2
Improving adherence for management of acute exacerbation of chronic obstructive pulmonary disease.
Am J Med. 2014 Nov;127(11):1097-1104. doi: 10.1016/j.amjmed.2014.05.033. Epub 2014 Jun 11.
5
Systemic Corticosteroid and Antibiotic Use in Hospitalized Patients With Chronic Obstructive Pulmonary Disease Exacerbation.
Ann Pharmacother. 2019 Feb;53(2):144-150. doi: 10.1177/1060028018799696. Epub 2018 Sep 3.
9
Sex Differences in Veterans Admitted to the Hospital for Chronic Obstructive Pulmonary Disease Exacerbation.
Ann Am Thorac Soc. 2019 Jun;16(6):707-714. doi: 10.1513/AnnalsATS.201809-615OC.

本文引用的文献

1
Glucocorticoid-induced hyperglycaemia in respiratory disease: a systematic review and meta-analysis.
Diabetes Obes Metab. 2016 Dec;18(12):1274-1278. doi: 10.1111/dom.12739. Epub 2016 Aug 4.
2
Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.
Chest. 2015 Apr;147(4):999-1007. doi: 10.1378/chest.14-0655.
3
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.
Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30. doi: 10.1186/1710-1492-9-30.
7
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.
Respir Med. 2009 Jul;103(7):975-94. doi: 10.1016/j.rmed.2009.01.003. Epub 2009 Apr 15.
8
Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly.
J Gen Intern Med. 2002 Sep;17(9):717-20. doi: 10.1046/j.1525-1497.2002.10649.x.
9
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.
J Clin Endocrinol Metab. 2002 Mar;87(3):978-82. doi: 10.1210/jcem.87.3.8341.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验